Clinical Trials Logo

Clinical Trial Summary

A randomized, evaluator-blinded study to assess skin irritation and skin sensitization of HP-1050 transdermal system (HP-1050) in comparison to XULANE patch in healthy female volunteers.


Clinical Trial Description

This is a dual-center, evaluator-blinded, randomized phase 1 study evaluating skin irritation and skin sensitization of HP-1050 transdermal system in comparison to XULANE patch in healthy female volunteers. The study will consist of a 4-week Screening Phase and a Treatment Phase. The Treatment Phase will consist of the following periods: an Induction Period, a Rest Period followed by a Challenge Period and if needed, a Re-Challenge Period. ;


Study Design


Related Conditions & MeSH terms

  • Cumulative Irritation and Sensitization

NCT number NCT04624867
Study type Interventional
Source Noven Therapeutics
Contact Study Director
Phone 305 253 5099
Email ClinicalTrials@noven.com
Status Recruiting
Phase Phase 1
Start date November 3, 2020
Completion date January 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT04094025 - Irritation and Sensitization Study of d-Amphetamine Transdermal System Phase 1